Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
Cytokinetics (CYTK) describes its evolution into a fully integrated specialty biopharmaceutical company after global approvals of MYQORZO (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in the U.S., Europe and China. The drug, a cardiac myosin inhibitor, launched in the U.S. in early 2026, with European and China commercialization rolling out through partners.
The company’s Vision 2030 strategy targets two product approvals across three indications and at least 10 new molecular entities, centered on muscle biology. Late‑stage programs include omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for a subset of HFpEF, plus early neuromuscular candidate CK‑089.
Cytokinetics has monetized part of future MYQORZO, omecamtiv mecarbil and ulacamten sales through revenue‑interest agreements with Royalty Pharma, and details extensive global patent coverage for its lead assets, with key aficamten patents potentially extending into the late 2030s and early 2040s.
Cytokinetics reported fourth-quarter and full-year 2025 results as it transitions into a commercial-stage company with MYQORZO. Revenue reached $88.0 million for 2025, up from $18.5 million in 2024, driven by $52.4 million from a technology transfer to Bayer and $15.0 million of MYQORZO approval milestones under the Sanofi agreement.
The company ended 2025 with about $1.22 billion in cash, cash equivalents and investments, including $100 million drawn from a Royalty Pharma loan. R&D expenses were $416.0 million and G&A expenses $284.3 million, reflecting clinical advancement and commercial build-out. Net loss widened to $784.9 million, or $(6.54) per share.
MYQORZO (aficamten) was approved for symptomatic obstructive hypertrophic cardiomyopathy in the U.S., China and Europe, with a U.S. launch underway and a Germany launch planned in Q2 2026. For 2026, the company guided to GAAP combined R&D and SG&A expenses of $830 million to $870 million.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting a significant ownership position in Cytokinetics, Inc. common stock as of 12/31/2025.
The firm reports beneficial ownership of 17,716,372 shares, representing 14.5% of the outstanding common stock. It has sole voting power over 17,330,683 shares and sole dispositive power over 17,700,030 shares, with no shared voting or dispositive power.
T. Rowe Price states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Cytokinetics, and it expressly denies being the beneficial owner of the securities beyond what is required for reporting.
Cytokinetics reported that the European Commission has approved MYQORZO® (aficamten) tablets at 5 mg, 10 mg, 15 mg and 20 mg strengths. The drug is indicated for adult patients with symptomatic, obstructive hypertrophic cardiomyopathy classified as New York Heart Association class II–III. This approval allows Cytokinetics to offer a novel allosteric, reversible inhibitor of cardiac myosin motor activity as a treatment option for this specific heart condition across the European Union.
Cytokinetics executive Andrew Callos reported an option exercise and share sale. On 02/05/2026, the EVP and Chief Commercial Officer exercised 15,000 non-qualified stock options at $23.26 per share and received 15,000 shares of common stock.
That same day, he sold 15,000 shares of common stock at $61.93 per share, leaving him with 50,440 shares of common stock held directly and 84,000 stock options remaining. The reported options were originally granted on 03/31/2022 and are scheduled to vest over four years, with an expiration date of 03/31/2031.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an option exercise and matching share sale in company common stock. On February 2, 2026, he exercised 886 shares under an incentive stock option at $37.63 per share.
The same day, he sold 886 common shares at $62.10 per share. After these transactions, Callos directly held 50,440 common shares and 886 incentive stock options. The option grant vests in equal monthly installments over four years from the grant date.
Cytokinetics director James M. Daly reported receiving company stock as board compensation. On January 15, 2026, he acquired 197 shares of Cytokinetics common stock at $63.44 per share. These fully vested shares were received in lieu of a cash retainer under an equity-in-lieu-of-cash option available to members of the board of directors. Following this transaction, Daly beneficially owned 197 shares of Cytokinetics common stock in direct ownership.
Cytokinetics director Nancy Wysenski reported receiving additional company stock as part of her board compensation. On 01/15/2026, she acquired 98 shares of common stock at a reported price of $63.44 per share, taken in lieu of a cash retainer under an equity-in-lieu-of-cash option available to board members. After this transaction, she beneficially owned 30,971 shares of Cytokinetics common stock, held directly.
Cytokinetics director Wendell Wierenga reported a routine equity compensation transaction. On January 15, 2026, he acquired 98 shares of Cytokinetics common stock at $63.44 per share. According to the footnote, these fully vested shares were received in lieu of a cash retainer under an equity-in-lieu-of-cash option available to board members. After this grant, he beneficially owns 32,542 common shares directly.
Cytokinetics director Edward M. Kaye, M.D. reported receiving additional company stock as part of his board compensation. On 01/15/2026, he acquired 197 shares of Cytokinetics common stock at $63.44 per share. According to the filing, these were fully vested shares issued in lieu of a cash retainer under an equity-in-lieu-of-cash option available to board members. After this transaction, Dr. Kaye directly owned 10,174 shares of Cytokinetics common stock.